A genetically engineered herpes virus may offer a new and effective treatment for advanced melanoma, providing hope for ...

A class of antivirals called Pin1 inhibitors could reduce or stop outbreaks of herpes simplex virus 1 (HSV-1), the common ...

After rejecting Replimune’s melanoma drug RP1 this summer, the FDA has accepted the biotech’s resubmission of an approval ...

FDA has accepted Replimune’s RP1 resubmission for advanced melanoma treatment. ・Prescription Drug User Fee Act decision date ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of ...

The U.S. Food and Drug Administration (FDA) has accepted Replimune's BLA resubmission for RP1 in combination with nivolumab, which targets advanced melanoma in patients who have not responded to prior ...

The statements regarding Herpafend have not been evaluated by the Food and Drug Administration (FDA). This product is not ...

Herpes is an incurable virus that spreads via physical contact in the mouth or genitals. However, medication can limit ...

They disable our defenses and hijack the cellular machinery in order to multiply successfully. For example, the herpes ...

Genital warts and herpes can often be mistaken for each other, but there are key signs that can help you distinguish the two.